Abstract | Phosphate is critical for the maintenance of skeletal integrity, is a necessary component of important biomolecules, and is central to signal transduction and cell metabolism. It is becoming clear that endocrine communication between the skeleton, kidney, and the intestine is involved in maintaining appropriate serum phosphate concentrations, and that the kidney is the primary site for minute-tominute regulation of phosphate levels. The identification of genetic alterations in Mendelian disorders of hypophosphatemia and hyperphosphatemia has led to the isolation of novel genes and the identification of new roles for existing proteins-such as fibroblast growth factor 23 and its processing systems, the coreceptor α-klotho, and phosphate transporters-in the control of renal phosphate handling. Recent findings also indicate that fibroblast growth factor 23 has feedback mechanisms involving parathyroid hormone and vitamin D that control phosphate homeostasis. This Review will highlight genetic, in vitro and in vivo findings, and will discuss how these clinical and experimental discoveries have uncovered novel aspects of renal phosphate handling and opened new research and therapeutic avenues.
Introduction serum phosphate levels are regulated by complex processes between the intestine, skeleton, and the kidneys. the maintenance of appropriate serum phosphate levels is critical for proper bone development and skeletal integrity. Phosphorus is also a necessary component of Dna and rna, and is essential for cellular metabolism as an energy source in the form of atP. 1 Phosphate is abundant in the diet, and intestinal absorption is efficiently regulated. 1 However, the mechanisms of phosphate handling in the kidney, the most critical organ for maintaining shortterm serum phosphate concentrations, are incompletely understood. the investigation of the molecular etiology of mendelian disorders characterized by disturbed renal ion homeostasis has been instrumental in identifying new regulators that guide renal phosphate handling. this review will address major factors involved in renal phosphate metabolism, including fibroblast growth factor 23 (FGF23), parathyroid hormone (PtH), and vitamin D, and will consider disorders of hypophosphatemia and hyperphosphatemia, the study of which has identified novel systems important for phosphate balance. recent advances involving a novel intrarenal signaling axis upstream of phosphate reabsorption will also be discussed.
Phosphate regulation
Phosphate, which comprises approximately 1% of total body weight, is widely distributed in the soft tissues of the body, both in inorganic form and as a component of organic molecules, including nucleic acids, membrane phospholipids, and other phosphoproteins. However, these nonosseous phosphates comprise less than 20% of the total body content of phosphate. the remainder is stored in the bone matrix. in humans, the average phosphate intake in adults ranges from 800 mg per day to 1,600 mg per day;
2 this large range is primarily a result of the high phosphate levels in western diets. the normal range for serum phosphate level in adults is 0.5-1.5 mmol/l; 3 in children, serum phosphate levels are higher and decrease with age. 4 Phosphate ingested through the diet is initially absorbed by the small intestine via an active, sodium-dependent process and a passive, diffusional, load-dependent process. 5 the type ii sodium-phosphate co-transporters are responsible for the majority of physio logical phosphate transport. three type ii sodium-phosphate co-transporters exist: nPt2a (slC34a1), nPt2b (slC34a2), and nPt2c (slC34a3). nPt2a is primarily expressed in the apical brush border membrane of the renal proximal tubule and is central to the process of renal phosphate reabsorption. nPt2b is primarily expressed in the small intestine and is regulated by vitamin D. nPt2b has a low affinity for phosphate, and humans with nPt2b-inactivating mutations do not have reduced serum phosphate levels, as may be expected in the absence of a key transporter. 6 However, studies in a conditional npt2b-null mouse model demonstrated that the npt2b transporter has a central role in active intestinal phosphate absorption. 7 interestingly, the deletion of npt2b resulted in an increase in the expression of npt2a in the renal proximal tubule and serum phosphate concentrations remained normal, most likely owing to compensatory renal reabsorption. Changes in intestinal phosphate absorption may, therefore, affect renal phosphate handling, perhaps indirectly through alterations in serum phosphate concentrations, or possibly through the production of intestinally derived circulating peptides. 8 these findings indicate that intestinal phosphate absorption may have important regulatory pathways that are yet to be uncovered.
the skeleton contains the largest reservoir of phosphate in the body. Here, phosphate is primarily complexed with calcium in the form of hydroxyapatite crystals, which constitute the main inorganic component of the mineralized bone matrix. the majority of phosphate retained in the body is deposited in bone as crystalline hydroxyapatite (which constitutes 85% of bone) or as amorphous calcium phosphate (which makes up the remaining 15%). 9 if the serum phosphate concentration decreases, phosphate is resorbed from bone through the activity of PtH and vitamin D. 10 the kidney is the major organ involved in the regulation of minute-to-minute phosphate homeostasis; approximately 70% of filtered phosphate is reabsorbed within the proximal tubule where the sodium-phosphate co-transporters nPt2a and nPt2c are expressed. 2 Phosphate transport across the renal proximal tubular cell is largely unidirectional and involves uptake across the brush border membrane, translocation across the cell, and efflux at the basolateral membrane. the overall rate-limiting step in the reabsorptive process is phosphate uptake at the apical membrane; consequently, this cell surface is a major site of phosphate regulation. 1 npt2a and, to a lesser extent, npt2c, actively transport phosphate from the phosphate-rich lumens of nephrons into proximal tubule cells. in mice, npt2a is responsible for approximately 70% of active phosphate transport, 11 with npt2c probably transporting the remaining 30%. npt2c, which has a more restricted expression pattern than npt2a, is expressed in the brush border membrane of the renal proximal tubule, and was originally thought to primarily play a role in neonatal phosphate balance. 12 in humans, nPt2c might have a larger role in renal phosphate reabsorption, as inactivating mutations in the gene encoding nPt2c lead to a hypophosphatemic syndrome, 13, 14 as will be discussed. 15 an enzyme that produces the active form of vitamin D-1,25-dihydroxyvitamin D-and increases calcium reabsorption in the renal distal convoluted tubule (DCt). PtH also stimulates the release of calcium from bones into the extra cellular fluid by increasing osteoclastic bone resorption. 16 in addition to its effects on calcium, PtH is one of the best characterized hormonal regulators of serum phosphate concentrations. In vitro or in vivo delivery of PtH results in reduced expression of nPt2a and nPt2c in the apical membrane of the proximal tubule ( Figure 1) . 17 this effect results from the relatively rapid internalization and subsequent degrada tion of npt2a and npt2c proteins, 18, 19 and in the short term occurs independently of regulation of the expression of the co-transporters at a transcriptional level. 20 these effects are mirrored in patients with defects in PtH regulation: patients with hyperparathyroidism develop renal phosphate wasting, and individuals with hypoparathyroidism show increased renal phosphate reabsorption. sodium-phosphate co-transporter expression in the apical membrane of proximal tubule cells is regulated by PtH signaling through the type 1 PtH receptor (PtHr1) via protein kinase a (PKa) and protein kinase C (PKC), as well as through the mitogenactivated protein kinase (maPK) pathway, 21, 22 to control internalization and degradation.
1,25-dihydroxyvitamin D largely regulates serum phosphate concentration by increasing intestinal calcium and phosphate absorption. the opposing effects of PtH and vitamin D on the kidney and the intestine, respectively, balance phosphate levels while preserving calcium ion homeostasis. 23 recent findings indicate that both PtH and vitamin D production could be influenced by FGF23 in negative feedback loops (Figure 1 ), adding further complexity to this regulatory system.
FGF23
mutations in the FGF23 gene have been shown to cause autosomal dominant hypophosphatemic rickets (aDHr), 24 and FGF23 has a central role in phosphate regulation. 25 the FGF23 gene, which is composed of three exons encoding a 251-residue polypeptide, is located on the human chromosome 12p13. 24 although FGF23 messenger rna (mrna) can be detected at low levels in many tissues including the heart, liver, thyroid glands, parathyroid glands, and small intestine, it is predominantly expressed in bone 24 by osteoblasts, osteocytes, flattened bone-lining cells, and osteoprogenitor cells. 26 Full-length FGF23 (32 kDa) is the biologically active form of the protein and can be cleaved into 20 kDa and 12 kDa fragments. the N-terminal region of FGF23 contains a conserved FGF-homology domain, whereas the C-terminus comprises a unique 72 amino acid long tail. 27 the intracellular proteolysis and inactivation 24, 28 and stabilize the full-length active form of the protein. these genetic observations are supported by the finding that when full-length FGF23, the N-terminal fragment, or the C-terminal fragment is delivered in vivo, only the intact hormone causes a reduction in serum phosphate concentra tion. 27 interestingly, recent evidence supports the idea that the 72-residue C-terminal fragment of FGF23 can bind to an FGF receptor 1 (FGFr1)-klotho signaling complex in vitro, and competitively decrease bioactivity of FGF23 in vitro and in vivo. 29 Renal bioactivity of FGF23 in mice, increased dietary phosphate leads to increased serum phosphate concentrations and increased circulating FGF23; the reciprocal relationship occurs with low-phosphate diets. 30 these findings have also been reported in some human studies, but the effect of phosphate on FGF23 in humans seems to be less robust than it is in mice. [31] [32] [33] whether phosphate has direct effects on the skeleton to control the production and secretion of FGF23 is currently unknown. similar to PtH, FGF23 acts to reduce phosphate reabsorption in the proximal tubule. However, contrary to PtH, FGF23 reduces expression of renal vitamin D 1α-hydroxylase and increases expression of catabolic 25-hydroxyvitamin D 24-hydroxylase, thus leading to decreased circulating levels of 1,25-dihydroxy vitamin D (Figure 1) . 34 the transgenic overexpression of FGF23 results in marked hypophosphatemia 35, 36 owing to renal phosphate wasting through the downregulation of the cotransporters npt2a and npt2c. 35, 36 as expected, transgenic mice expressing human FGF23 have osteo malacia, 35, 36 which parallels the skeletal findings in patients with aDHr, X-linked hypophosphatemia (XlH), and tumorinduced osteomalacia (tio) (Box 1). Patients who have disorders of elevated FGF23 levels, such as aDHr and XlH, are said to have 'inappropriately low or normal' serum 1,25-dihydroxyvitamin D concentra tions, as the physiological response to the prevailing hypophosphatemia should be an increase in 1,25-dihydroxyvitamin D. Collectively, these observa tions are consistent with the existence of a negative feedback process between kidney and bone, as 1,25-dihydroxy vitamin D is known to stimulate FGF23 promoter activity in vitro 37, 38 and FGF23 production in vivo 39 ( Figure 1 ). the Fgf23-null mouse has the opposite phosphate phenotype to FGF23 transgenic mice, with severe hyperphosphatemia and elevated 1,25-dihydroxy vitamin D levels resulting in soft tissue calcifications, growth retardation, and abnormal bone mineralization. 40 ,41 a reduction in FGF23 bioactivity leads to increased circulating 1,25-dihydroxyvitamin D levels ( Figure 1 ), most likely through increased 1α-hydroxylase activity or expression 42 ( Figure 1 ), as has been observed in Fgf23-null mice, in mice null for the FGF23 co-receptor α-klotho, 40 ,41,43 and in some patients with hyper phosphatemic tumoral calcinosis. [44] [45] [46] Hyperphosphatemia is also observed in the Galnac transferase 3 (Galnt3)-null mouse, a model of familial tumoral calcinosis, 47 which arises from altered glycosylation and increased degradation of FGF23. 48 the relationship between FGF23 and vitamin D is confirmed by the fact that mating a Fgf23-null or klotho-null mouse with a 1α-hydroxylase (Cyp27B1)-null or VDR-null mouse results in a reversal of the hyperphosphatemia associated with genomic loss of Fgf23 or klotho. 42, 49 thus, the pathogenesis observed in Fg f23-null and klotho-null mice may largely be a result of the elevated 1,25-dihydroxy vitamin D concentrations.
other minerals, such as iron, have been suggested to alter FGF23 expression in humans, and can cause osteomalacia. 50 some patients receiving parenteral iron infusions have been reported to develop hypo phosphatemia and decreased serum levels of 1,25-dihydroxyvitamin D. 51, 52 Case reports have since demonstrated that serum FGF23 levels in several such patients increased significantly in response to the infusions of parenteral iron. 53, 54 although a striking relationship between iron infusion and elevated FGF23 levels is apparent, the mechanisms underlying these observations 
FGF23 bioactivity and α-klotho
to become biologically active, FGF23 binds to a signaling complex composed of the co-receptor α-klotho and an FGFr. 55 Klotho is expressed in a limited number of tissues including the choroid plexus, the parathyroid glands, and the kidney, 43 which indicates that circulating FGF23 has tissue-specific effects. In vitro evidence supports the idea that associations between FGFr1c and klotho form a receptor complex to elicit FGF23 signaling through the maPK cascade and phosphorylated erK1/2 (p-erK1/2). 55 interactions between multiple FGFrs and klotho have also been identified in vitro. 56 High levels of FGF23 signaling occur when klotho and FGFr1c are co-expressed in vitro, 55 and underscoring the importance of the formation of a klotho-FGFr receptor complex, this activity can be blocked by anti-FGF23 antibodies that disrupt associations between FGFr, FGF23 and klotho. 57 in further support of direct interactions between FGF23 and klotho, Fgf23-null and klotho-null animals have identical hyperphosphatemic phenotypes. 40, 41, 43, 58 additionally, a recessive, loss-of-function mutation in the human klotho gene resulted in impaired klotho expression and activity in vitro, and led to a severe tumoral calcinosis phenotype, most likely owing to endorgan resistance to FGF23. 44 interestingly, a case has also been reported where a novel balanced translocation with a breakpoint adjacent to the human klotho gene is associated with increased expression of α-klotho in the circulation. this genetic rearrangement was associated with elevated levels of FGF23 and PtH, and hypophosphatemic rickets, 59 but the molecular mechanisms underlying the phenotype are currently unknown.
in a study aimed at identifying the renal FGFr that mediates FGF23 bioactivity, Fgfr3-null and Fgfr4-null mice were mated to the Hyp mouse model of XlH. Genetic removal of these receptors did not reverse the hypophosphatemic phenotype observed in the Hyp mouse, 60 indicating that these receptors individually may not be the primary FGFrs that transduce FGF23 signaling with klotho in vivo. thus, whether FGFr1 and/or FGFr2 are responsible for FGF23-dependent signaling, or whether klotho can partner with multiple FGFrs in vivo, is currently unknown.
at least two isoforms of klotho are produced as a result of alternative splicing of the same gene. membranebound klotho is a 130 kDa single-pass transmembrane protein characterized by a large extracellular region (Kl1 and Kl2 domains) and a very short (10-residue) intracellular domain that does not possess signaling capabilities. 61 the secreted form of klotho is approximately 80 kDa and is spliced within exon 3 to result in a klotho protein that does not contain the transmembrane region, and is thus secreted into the circulation. 61 a third isoform of klotho ('cut Kl' or cKl), also found in the circulation, is derived by the proteolytic processing of klotho near the extracellular membrane surface. 62 although klotho permits FGF23 signaling when co-expressed with FGFrs in vitro, the mechanisms under lying FGF23 bioactivity in the kidney in vivo are unclear. in this regard, klotho protein and mrna have been mapped to the DCt, 43, 63 whereas FGF23 mediates effects on the co-transporters npt2a and npt2c and the vitamin-D-metabolizing enzymes within the proximal tubule 34, 35 ( Figure 2 ). Furthermore, in vitro experiments support the idea that the membrane-bound klotho isoform is capable of initiating FGF23-dependent maPK bioactivity. 63 in contrast to PtH, which has direct effects on the proximal tubule to regulate npt2a expression, 17 a study has demonstrated that following FGF23 injection, initial FGF23 activity (5-10 min) tested by the detection of p-erK1/2, occurs in the renal DCt, and is not localized with npt2a in the proximal tubule. 63 therefore, a spatial separation may exist between initial FGF23 bioactivity in the DCt and nPt2a. at this time, however, a novel, direct signaling process occurring in the proximal tubule following FGF23 delivery cannot be ruled out. soluble klotho, produced in the DCt, has also been proposed to have direct effects in the proximal tubule as a mediator of FGF23 activity. 64 additional mechanistic studies are needed to clarify the role of soluble klotho isoforms in phosphate handling, but increased activity of circulating soluble klotho could potentially explain the phenotype of the above-mentioned hypophosphatemic patient with the balanced translocation. 59 Klotho is an attractive thera peutic target for disorders involving increased FGF23 bioactivity, but it is necessary to determine which klotho isoforms are responsible for FGF23-mediated phosphate handling, and whether soluble forms of klotho regulate FGF23 activity within, as well as outside, the kidney.
FGF23 and PTH
the FGF23 co-receptor klotho is highly expressed in the parathyroid glands, which indicates a direct role for FGF23 in the regulation of PtH production. 43 independent, para llel studies have shown that FGF23 delivery to bovine parathyroid cells in vitro, or to rats in vivo, increases p-erK1/2 activity and reduces PtH mrna and circulating concentrations of PtH 65, 66 ( Figure 1) . the case of a patient with Jansen's metaphyseal chondrodysplasia caused by activating mutations in the type 1 PtH/PtH-related protein (PtHrP) receptor (PtHr1) provides further support for the existence of a PtH-FGF23 axis. 67 the patient had significantly elevated serum FGF23 levels, despite persistent hypophosphatemia, 67 which suggests that PtH might revieWs patients with primary hyperparathyroidism, 70 and PtH could potentially increase 1,25-dihydroxyvitamin D, which in turn, would increase FGF23. 39 the findings also indicate that additional regulatory loops may be involved in FGF23 production, and speculatively, that these loops may be physiologically 'prioritized' . in this regard, the hypophosphatemia associated with primary hyper parathyroidism may strongly suppress FGF23 production at the genomic level and might not permit PtHdependent increases in FGF23. Collectively, the findings underscore the complexity of phosphate homeostasis, and confirm that further studies are needed to resolve potentially new regulatory pathways involving FGF23, PtH, and vitamin D.
Disorders of hypophosphatemia
Autosomal dominant hypophosphatemic rickets as described earlier, aDHr is caused by gain-of-function mutations in FGF23 (Figure 2; table 2 ). aDHr is a rare, renal phosphate-wasting disorder characterized by hypophosphatemia, elevated serum FGF23 levels, inappropriately normal 1,25-dihydroxyvitamin D levels, normal PtH levels, and normocalcemia 71 (table 2) . in general, patients with aDHr present with bone pain, osteomalacia, fractures, and tooth abscesses, symptoms similar to those of patients with XlH. However, aDHr is unique among the hypophosphatemic syndromes in that the disease manifests in two distinct patient groups, either in children-with bone pain, weakness, and insufficiency fractures-or in adults, with low tubular maximum phosphate reabsorption per glomerular filtration rate (tmP/ GFr) and no extremity deformities, but sometimes with pseudofractures. 71 in addition, unaffected carriers of aDHr have been reported. 71 importantly, the degree of disease manifestation in aDHr correlates with serum FGF23 concentrations, where worse disease is associated with higher serum FGF23 levels. 72 
X-linked hypophosphatemia
XlH is the most common heritable phosphate-wasting disorder, occurring in approximately one in 20,000 births. 73 in contrast to aDHr, XlH is a fully penetrant dominant disorder with variable severity. 74 Patients with XlH present with defects similar to those of aDHr patients (table 2), but also manifest entheso pathy (calcifica tion of the tendons and ligaments). XlH is caused by inactivating mutations in PHEX (phosphateregulating gene with homologies to endopeptidases on the X chromosome), 75 a member of the m13 family of membrane-bound metallo proteases. Data indicate that there is no predominant PHEX mutation leading to XlH. 76 PHeX is expressed in osteoblasts and osteocytes, and odontoblasts in teeth. 77 serum FGF23 level is elevated in most patients with XlH (table 2) , [78] [79] [80] and is also elevated in Hyp mice (Box 1), which have approximately 10-fold higher concentrations of FGF23 than do wild-type controls. 81 Quantitative real-time reverse-transcriptase PCr analysis revealed that Fgf23 mrna is also elevated in the bone of Hyp mice. 82 additionally, renal npt2a expression is reduced by approximately 50% in the Hyp mouse model. 83 these findings provide support for a physio logical connection between PHeX activity and FGF23 expression.
Autosomal recessive hypophosphatemic rickets autosomal recessive hypophosphatemic rickets (arHr) is a disorder caused by Dentin matrix protein-1 (DMP1)-inactivating mutations. 84, 85 the biochemical phenotype of arHr is similar to that of aDHr and XlH (table 2), DmP1 is a member of the short integrin-binding ligand interacting N-linked glycoprotein (siBlinG) family of skeletal matrix proteins, 86 and is highly expressed in osteocytes and in canaliculi within the bone matrix. DmP1 has been proposed to have roles in canaliculi function 87 and regulating hydroxyapatite formation. 88 the Dmp1-null mouse (Box 1) has severe hypo phosphatemic rickets and marked elevation of Fgf23 levels. 84 Histomorphometric and electron microscopic analyses of bone biopsies from Dmp1-null mice and iliac crest bone biopsies from patients with arHr demonstrated malformed osteocytes and disorganization of the cannicular system. 84 Fgf23 was shown to be elevated in Dmp1-null osteocytes by in situ hybridization, consistent with the elevated serum levels. these findings revealed an important role for skeletal matrix protein in the differentiation of bone cells and in the downstream regulation of phosphate handling. mechanistic studies using the Dmp1-null mouse demon strated that loss of Dmp1 impairs osteocyte maturation and gene expression, leading to both elevated Fgf23 (Figure 2 ) and to the inappropriate expression of type i collagen and alkaline phosphatase in osteocytes, which may indicate a general cell defect. 84 the prevailing hypophosphatemia results in pathological changes in bone mineralization in this model, 84 which can be largely, but not completely, abrogated by the administration of a high-phosphate diet. importantly, Dmp1-null mice parallel the phenotypes of Hyp mice (and patients with arHr and XlH), which all share a distinctive bone histology character ized by periosteocytic lesions of non mineralized bone, 84 abnormal osteocyte morphology, 89 and an 'intrinsic' bone defect that cannot be completely resolved by increased delivery of phosphate. these findings suggest that PHeX may cause overexpression of FGF23 through a role in osteocyte maturation (Figure 2 ). Gene array analyses of cortical bone rna from Hyp mice shows alterations in components of Fgf and wnt signaling. 38 as both of these pathways are central to cell differentiation and skeletal development, these autocrine systems might either underlie, or be a response to, the potential differentiation defects observed in Hyp (XlH) and Dmp1-null (arHr) mice.
Tumor-induced osteomalacia tio is an acquired disorder of renal phosphate wasting induced by factors secreted by tumors, often from mesen chymal origin. 90 the biochemical and skeletal phenotypes of patients with tio are similar to those of patients with aDHr, XlH, and arHr, and patients with tio might also report weakness. studies of tio found that surgical removal of the tumor leads to a reversal of the hypophosphatemia and metabolic bone disease, 91, 92 which led to the idea that circulating factors produced by the tumor-referred to as phosphatonins-act on the kidney to reduce phosphate reabsorption. FGF23 mrna is highly expressed in tio tumors 34, 93, 94 (Figure 2) , and patients can have markedly elevated serum FGF23 levels, which rapidly return to control levels after tumor resection. 78, 95 in support of the phosphatonin theory, the transplant of tio tumor tissue into mice resulted in the original hypophosphatemic syndrome being mirrored in these animals. 96 hhrh Hereditary hypophosphatemic rickets with hypercalciuria (HHrH) was first described in a consanguineous Bedouin tribe.
97 similar to the disorders described above, HHrH is characterized by hypophosphatemia with rickets and short stature, but the biochemical characteristic that distinguishes this disorder from the FGF23-related diseases such as aDHr and XlH is the notable increase in serum 1,25-dihydroxyvitamin D that occurs as a compensatory response to the prevailing hypophosphatemia. 97 affected individuals also have markedly elevated urine calcium excretion with increased intestinal absorption of phosphorus and calcium, which can lead to nephrolithiasis.
Homozygosity mapping was performed to identify the genetic defect responsible for HHrH. using this approach, the disease locus was narrowed to the portion of chromosome 9q34 containing the SLC34A3 gene, which encodes nPt2c (table 2) . 13, 14 Direct Dna sequencing of nPt2c in unrelated HHrH kindreds led to the identification of recessive, single-nucleotide deletions, compound heterozygous deletions and missense mutations. these mutations are predicted to be loss-of-function mutations, and most likely reduce renal phosphate absorption through decreasing the apical membrane expression of nPt2c or the uncoupling of sodium-phosphate co-transport in the proximal tubule.
98,99 a major implication of the identification of the changes in nPt2c that occur in HHrH is that this transporter seems to have an important role in renal inorganic phosphate reabsorption throughout life, and not simply a role in phosphate homeostasis early in life, as previously hypothesized. the fact that NPT2c mutations lead to disease in humans, while genetic deletion of Npt2c does not lead to disease in mice, 100 may also indicate that this transporter has a more important role in humans than in other species. mutations in NPT2a and na + /H + exchanger regulatory factor (NHERF), which regulates npt2a expression and activity, have also been reported to lead to hypophosphatemia in humans. 101, 102 Further in vitro and in vivo studies will be useful in determining the molecular mechanisms underlying the syndromes involving nPt2a and nHerF. 104 this key glycosylation site probably prevents intracellular degradation of FGF23 at the rXXr motif by sPC-like enzymes in the trans-Golgi network 104 ( Figure 2 ). Patients with tumoral calcinosis with inactivating GALNT3 mutations produce only minute amounts of intact FGF23, which leads to hyperphosphatemia. 48 in support of this finding, subsequent analysis of the Galnt3-null mouse revealed that this mouse model has reduced circulating intact Fgf23 levels and increased circulating fragments of Fgf23, but increased Fgf23 mrna in the bone. these mice display the expected physiological response to increased circulating phosphate and 1,25-dihydroxy vitamin D levels-increased Fgf23 transcription-but the defective O-glycosylation in these mice reduces levels of intact, bioactive Fgf23. 47 the tumoral calcinosis phenotype is also caused by recessive inactivating mutations in the conserved FGFlike domain of FGF23 (Figure 2 ; table 2), which destabilize the full-length form of the hormone. [105] [106] [107] strikingly, patients with mutations in GALNT3 or FGF23 both have low intact serum FGF23 levels, but significantly elevated C-terminal fragments of FGF23, 46, 48 which probably repre sents an attempt to increase FGF23 production. the biochemical profile of elevated C-terminal serum FGF23 levels in conjunction with low intact serum FGF23 levels is specific to patients with tumoral calcinosis caused by mutations in GALNT3 or FGF23. importantly, in vitro studies have now shown that recombinant FGF23 carrying FGF23 mutations that cause tumoral calcinosis has defective O-glycosylation, which makes this form of FGF23 more prone to intracellular degradation. 108 these observations provide the likely explanation for the identical serum FGF23 profile of patients who have tumoral calcinosis caused by either mutant FGF23 or GALNT3. 108 Hyperostosis-hyperphosphatemia syndrome (HHs) was originally described as being a separate disorder from tumoral calcinosis owing to radiological findings of abnormalities involving cortical bone hyperostosis typically not observed in patients with tumoral calcinosis. 109 However, mutational analysis revealed that patients with HHs had mutations identical to those in patients diagnosed with tumoral calcinosis caused by GALNT3 mutations and the same inappropriate intact and C-terminal FGF23 concentrations, 106, 109 indicating that the two syndromes are allelic. the molecular mechanisms underlying the large range of phenotypes that exist in patients with tumoral calcinosis and HHs are currently unknown. a homozygous mutation in klotho, His 193 arg, was shown to be a third cause of tumoral calcinosis in a single patient. 44 the patient presented with hyperphosphatemia, hypercalcemia, elevated PtH levels, and ectopic calcifications in the heel and brain. 44 the missense mutation was localized within a highly conserved region in exon 1, and present in all isoforms of klotho. In vitro analysis of the mutant protein illustrated decreased mature, glycosylated klotho expression, as well as reduced FGF23-dependent signaling through maPK; this mutation is therefore assumed to prevent FGF23 bioactivity in vivo. in contrast to patients who have tumoral calcinosis caused by mutations in GALNT3 or FGF23, the patient with tumoral calcinosis caused by a mutation in klotho had significantly elevated serum levels of intact and C-terminal FGF23 (>150-fold greater than the normal mean level). this increase was probably a response to the notable hyperphosphatemia and elevated 1,25-dihydroxyvitamin D level in this patient, as the FGF23 gene itself was not altered. these findings provide support for the existence of direct interactions between FGF23 and klotho.
CKD and emerging therapeutics as has been described, a large body of evidence supports the idea that FGF23 and its signaling complexes are central to renal phosphate homeostasis. in clinical practice, the most common form of pathological change involving serum phosphate is hyperphosphatemia from chronic kidney disease (CKD), a disease now estimated to affect one in eight individuals in the us. 110 the increase in serum phosphate levels in these patients is caused by several different mechanisms, the most important of which is reduced renal phosphate excretion. a further aggravating factor in patients with CKD is secondary hyperparathyroidism, which is manifested in a large proportion of patients, and can lead to increased bone resorption and further elevations in phosphate arising from skeletal stores. 111 owing to the increased serum phosphate levels that occur in patients with CKD and the known physiological increase in circulating FGF23 levels that occur in response to hyperphosphatemia, it was hypothesized that patients with advanced renal disease might have elevated levels of FGF23. 112 this has now been demonstrated using multiple FGF23 serum assays. 78, 95 importantly, in CKD patients grouped into quartiles according to their serum phosphate concentrations, patients with elevated FGF23 levels had a 5-6-fold increase in the odds for mortality. 113 Furthermore, the increased circulating FGF23 may be in part responsible for the suppressed 1,25-dihydroxyvitamin D concentrations observed in patients with CKD, as FGF23 is known to reduce renal 1α-hydroxylase and stimulate catabolic 24-hydroxylase. 39 Potential treatments for the heritable hypophosphatemias were initially examined in model systems, revieWs and testing is now underway in clinical trials using inactivating monoclonal antibodies targeting FGF23. in the Hyp mouse, anti-FGF23 completely reversed the hypophosphatemia and associated bone disease, including the osteomalacia and reduced bone length, after 4 weeks of treatment. 57 Humanized monoclonal anti-FGF23 therapy ('Krn23') is now in a phase i clinical trial in patients with XlH. 114 it is tempting to speculate that similar therapies could be used to modulate renal phosphate and vitamin D metabolism, or potentially PtH production, in patients with early stage CKD. in patients with impaired renal function, suppression of FGF23 activity may lead to elevated 1,25-dihydroxyvitamin D levels, but such an approach could also increase renal phosphate reabsorption, and further raise serum phosphate concentrations. Certainly, additional studies examining the role of FGF23 in animal models are needed to relate these observations to potential future therapeutics targeting FGF23 in CKD.
Conclusions
in summary, the regulation of renal phosphate handling is complex and is controlled by overlapping endocrine processes. PtH is primarily responsible for calcium balance, but plays important roles in kidney phosphate homeostasis by acting directly on the proximal tubule. the molecular discoveries associated with the heritable hypophosphatemic disorders and tumoral calcinosis demonstrate that FGF23 is central to the metabolism of phosphate and vitamin D in humans. increased FGF23 bioactivity is associated with renal phosphate loss and inappropriately normal 1,25-dihydroxyvitamin D concentrations, whereas decreased FGF23 bioactivity results in increased renal phosphate reabsorption and elevated 1,25-dihydroxyvitamin D levels. Furthermore, the identification of nPt2c-inactivating mutations has revealed novel renal mechanisms of phosphate reabsorption. Finally, the newly discovered relationships between the kidney, skeleton, and intestine will provide new and important insights into phosphate homeostasis both in health and in disease.
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